Rubius Therapeutics Inc

Rubius Therapeutics — Technical Presentation (March 2021)

39 slides from Rubius Therapeutics's technical presentation, Mar 15, 2021

  1. Slide 1: Realizing the Power of RED: Initial Clinical Results from RTX-240 Phase 1 Trial

    REALIZING THE POWER OF RED™ A NEW ERA IN CELLULAR MEDICINEInitial Clinical Results from RTX-240 Phase 1 Clinical TrialMARCH 15, 2021 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking StatementsThis presentation may contain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future

  3. Slide 3: Single-Agent Activity with RTX-240 in Advanced Solid Tumors

    Single-Agent Activity with RTX-240 in Advanced Solid Tumors – Two Responses with Favorable Safety ResultsWe Aim to Realize the Power of Immune Agonists by Enabling a Broad Therapeutic WindowThese Initial Clinical Results Increase the Probability of Success of our Oncology Pipeline3

  4. Slide 4: The Promise of Red Cell Therapeutics: The Future of Cellular Therapy

    The Promise of Red Cell Therapeutics™: The Future of Cellular TherapyEARLY PROGENITOR CELLSGENETIC ENGINEERING WITH LENTIVIRUSRED PLATFORM®EXPANSION & DIFFERENTIATIONENUCLEATION & MATURATIONRED CELL THERAPEUTICSINGLE HEALTHY O- DONOR100-1000’s OF DOSESFEATURES • Allogeneic, off the-shelf cellular th

  5. Slide 5: RTX-240 Designed to Deliver Two Key Agonist Signals to the Immune System

    RTX-240 is Designed to Deliver Two Key Agonist Signals to the Immune SystemRTX-240 | (4-1BBL + IL-15TP)BROAD IMMUNE SYSTEM STIMULATIONDESIGNED TO STIMULATE ADAPTIVE AND INNATE IMMUNE CELL AGONIST PATHWAYSNK)POTENTIAL BENEFITS:• Activate existing agonist pathways leading to enhanced potency • Overcom

  6. Slide 6: mRBC-240 Resulted in No Liver Toxicity and Inhibited Tumor Growth

    mRBC-240 Resulted in No Liver Toxicity and Significantly Inhibited Tumor Growth as MonotherapySERUM ALT B16F10 LUNG METASTASES MODEL250200200 15015010050100500 0mRBC-240 showed no liver toxicity in vivo4 Doses, 1x109 cells day 0, 3, 7, 10; Sacrifice day 18mRBC-240 reduced tumor burden and was equiva

  7. Slide 7: RTX-240 Proposed Mechanism of Action

    RTX-240 Proposed Mechanism of Action1 ACTIVATION2 EXPANSION3 TRAFFICKING4 TUMOR KILLING1T cellNK cell RTXRBCNK cell3 4T cellHLA-DR in T and NK cells 2 White pulpNKp30, NKG2D:NKG2A ratioTotal CD8+ memory T cells and NK cellsT cell Red pulp RTX NKcellRBCPotential for enhanced efficacy and safety versu

  8. Slide 8: RTX-240 Led to Clinical Benefit in Certain Patients with Pretreated Advanced Solid Tumors

    RTX-240 Led to Clinical Benefit in Certain Patients with Pretreated Advanced Solid TumorsPARTIAL RESPONSE CONFIRMEDMETASTATIC ANAL CANCERPARTIAL RESPONSE UNCONFIRMED METASTATIC UVEAL MELANOMASTABLE DISEASE*NON-SMALL CELL LUNG CANCERSTABLE DISEASESOFT TISSUE SARCOMASTABLE DISEASEPANCREATIC CANCERSTAB

  9. Slide 9: Clinical Trial Design & Initial Data Summary

    CLINICAL TRIAL DESIGN & INITIAL DATA SUMMARY CHRISTINA COUGHLIN, M.D., PH.D., CHIEF MEDICAL OFFICER9

  10. Slide 10: RTX-240 Clinical Development Plan

    RTX-240 Clinical Development PlanMONOTHERAPY Relapsed/refractory (R/R) or locally advanced solid tumors1e8 (n=2) Q4W IV1e9 (n=3) Q6W IV3e9 (n=3) Q4W IV1e10 (n=4) Q4W iv1e10 (n=3) Q4W iv/it*3e10 Q4W IV (n=1) Open to Enrollment**cFurther explore dose & intervalRTX-240 + PD-1 Relapsed/Refractory Solid

  11. Slide 11: Initial RTX-240 Solid Tumor Clinical Data Summary and AML Update

    Initial RTX-240 Solid Tumor Clinical Data Summary and AML UpdatePHASE 1 Solid Tumor Overview and Initial Clinical DataPHASE 1 AML OverviewOverview: • • • • Efficacy • Safety: • Pharmacodynamic (PD) effects: • Dose response: • •• 5 patients treated across 2 dose levels • Reported trafficking data fro

  12. Slide 12: Patient Case Studies

    ......·.·.·.·.·..•.•..• . i·.(·.;(•..R...ubiusTherapeutics •••••••••PATIENT CASE STUDIES12

  13. Slide 13: Confirmed Partial Response in Anal Cancer with 54% Reduction in Target Lesions

    Confirmed Partial Response in Anal Cancer with 54% Reduction in Target LesionsCASE HISTORY1 2 3Baseline June 20204 5C3D1 Aug 2020 (2 months) -11% target lesions (SD)C5D1 Oct 2020 (4 months) -34% target lesions (PR)prior to enrollment • Treated with RTX-240 in the 1e8 Q4W iv cohort in metastatic 3L s

  14. Slide 14: Unconfirmed Partial Response in Metastatic Uveal Melanoma

    Unconfirmed Partial Response in Metastatic Uveal Melanoma with Complete Resolution of Hepatic Target Lesion at 16 Weeks CASE HISTORY 1 2Hepatic target lesionBaseline Oct 2020 Target Lesion3Cycle 3 Day 1 Dec 2020 (2 months) Target Lesion (SD)1e10 Q4W iv cohort in the 2L settingCycle 5 Day 1 Feb 2021

  15. Slide 15: RTX-240 Induced Complete Regression of Liver Lesions in Uveal Melanoma

    RTX-240 Induced Complete Regression of 14 of 15 Lesions in the Liver in Metastatic Uveal Melanoma Patient1 2 3Baseline Oct 2020 Non-Target Lesion (9mm)1 2Cycle 3 Day 1 Dec 2020 (2 months) Non-Target Lesion (9mm)3Cycle 5 Day 1 Feb 2021 (4 months) Non-Target Lesion (7mm)Lower liver images Non-target l

  16. Slide 16: Initial Solid Tumor Clinical Data

    ......·.·.·.·.·..•.•..• . i·.(·.;(•..R...ubiusTherapeutics •••••••••INITIAL SOLID TUMOR CLINICAL DATA16

  17. Slide 17: Patient Baseline Characteristics

    Patient Baseline CharacteristicsAge (median, range) Gender (Male/Female) Race/Ethnicity Non-Hispanic/Non-Latino Hispanic/Latino Disease setting1 Colorectal/lower GI cancers, n Melanoma, n Other cancers, n Lines of prior therapy in the metastatic setting, median (range) Prior anti-PD-1/PD-L1 Prior ip

  18. Slide 18: Treatment-Related Adverse Events and Immune-Related Adverse Events

    Treatment-Related Adverse Events (AE)* and Immune-Related Adverse Events – No Grade 3/4 Adverse Events (n=16)ADVERSE EVENT PREFERRED TERMFatigue Chills Decreased Appetite Arthralgia (joint pain) Nausea Fever Myalgia (muscle pain) Dysgeusia (altered taste) Hyperhidrosis (excessive sweating)GRADE 1 N

  19. Slide 19: Best Response Observed in Patients with Solid Tumors

    Best Response Observed in Patients with Solid TumorsCLINICAL EFFICACY RESULTS• The best response is recorded from the start of the treatment until disease progression with 14 patients evaluable for best response• Patients are considered evaluable for response with measurable disease at baseline (per

  20. Slide 20: Time to Tumor Response and Time on Therapy

    Time to Tumor Response and Time on Therapy• Two partial responses observed at different iv dose levels* • Four patients with SD lasting >12 weeks 1 • Treatment ongoing in 4 patients** • Enrollment continues in new Phase 1 cohortsTime on Treatment (Days)1 Patient discontinued due to clinical disease

  21. Slide 21: Initial Pharmacodynamic Data

    ....•.·•·•·•·······. ·•·· i{(Rub ius The rap eutics •••••••••••••••INITIAL PHARMACODYNAMIC DATA21

  22. Slide 22: RTX-240 Induced Activation and Expansion of NK Cells and Memory CD8+ T Cells

    RTX-240 Induced the Activation and Expansion of Both NK Cells and Memory CD8+ T CellsNK CELL FUNCTIONMEMORY CD8+ T CELL FUNCTIONNKG2DHLA-DRNKG2AHLA-EDying tumor cell (attacked by the NK cell)HLA-DRMHC Class IDying tumor cell (attacked by the T cell)NKp30 B7H6T cell receptor (TCR)• NK cell activity i

  23. Slide 23: RTX-240 Stimulated Adaptive and Innate Immunity, Supporting Proof of Mechanism

    RTX-240 Stimulated Adaptive and Innate Immunity, Supporting Proof of Mechanism• Demonstrated activation and/or expansion of NK or memory CD8+ T cells or both in all patients with solid tumors (n=16) ▪ Resulted in partial responses in 2 patients• Induced two key NK cell subsets associated with cytoto

  24. Slide 24: RTX-240 Induced Activation and Expansion of NK and T Cell Populations

    RTX-240 Induced Activation and Expansion of NK and T Cell Populations (n=16)NK CELL ACTIVATION AND EXPANSION MEMORY CD8 T CELL ACTIVATION AND EXPANSIONLow dose = 1e8-3e9 cells/dose (n=8); High dose = 1e10-3e10 cells/dose (n=8)RTX-240 activated and expanded NK and T cells across RTX-240 dose levelsIn

  25. Slide 25: RTX-240 Induced Expansion and Activation Receptor Expression in Key NK Subsets

    RTX-240 Induced Expansion and Activation Receptor Expression in Key NK Cell Subsets (n=8)KEY NK SUBSETS INDUCED BY RTX-240ACTIVATION AND INHIBITORY RECEPTORS INDUCED BY RTX-240High dose = 1e10-3e10 cells/dose (n=8)RTX-240 expanded differentiated (CD56dim) and immature NK cells (CD56bright) in lympho

  26. Slide 26: Tumor Infiltration Data: Solid Tumors and AML

    TUMOR INFILTRATION DATA: SOLID TUMORS AND AML26

  27. Slide 27: Tumor Trafficking from Periphery into the Tumor Microenvironment

    Tumor Trafficking from Periphery into the Tumor Microenvironment• Trafficking of both T and NK cells was observed in 3/5 patients (1.6 to 10-fold increases) ▪ Shown in patients with metastatic mesothelioma (n=1), metastatic soft tissue sarcoma (n=1) and refractory AML (n=1) ▪ Tumor infiltration was

  28. Slide 28: Case 1: Metastatic Mesothelioma with NK and T Cell Trafficking

    CASE 1: Metastatic Mesothelioma with NK and T cell Trafficking 10-Fold Increase in Percentage of NK Cells in Refractory DiseaseGmzB+ T cell trafficking NK cell traffickingArchival diagnostic biopsy On-treatment biopsy Day 34 (2 iv doses) On-treatment biopsy Day 34 (2 iv doses)GmzBCD3 (T cells) CD8 (

  29. Slide 29: Case 2: AML Biopsy Images Show Increased Bone Marrow Cellularity

    Case 2: Acute Myeloid Leukemia (AML) Biopsy Images Increased Cellularity in Bone Marrow with activated NK and T Cell TraffickingBaseline Pre-treatmentOn-treatment Cycle 2 Day 8 (2 doses, Day 36) On-treatment (Cycle 2, after 2 doses, Day 36)On-treatment (Cycle 3, after 3 doses, Day 64)GmzBCD3 (T cell

  30. Slide 30: RTX-240 Clinical Development Plan

    ......·.·.·.·.·..•.•..• . i·.(·.;(•..R...ubiusTherapeutics •••••••••RTX-240 CLINICAL DEVELOPMENT PLAN30

  31. Slide 31: Using NK and T Cell Biology to Select Development Indications

    Using the Biology of the NK and T cell Response to Select Development IndicationsNK CELLS AS RTX-240 TARGETS METHODOLOGYNK cell (activated by RTX-240)NKG2DNKp30NKG2AB7-H6MHC Class IDying tumor cell (attacked by the NK cell)• Key factors leveraged to identify potential indications among solid tumors

  32. Slide 32: Biology of Target Cells Informs Indication Selection

    Biology of Target Cells Informs Indication Selection and Correlates with Responses in Anal and Uveal Melanoma Patients• Cancer indications ranked the highest in this analysis include ▪ Upper GI cancers (Gastric/esophageal cancer) ▪ AML ▪ Lower GI cancers (anal, colorectal cancer) ▪ Metastatic uveal

  33. Slide 33: Key Takeaways from Initial Data

    Key Takeaways from Initial Data• RTX-240 demonstrated a favorable, emerging safety results across dose levels• Single-agent activity with partial responses per RECIST v1.1 in two patients• Pharmacodynamic effects demonstrated the activation and expansion of the key NK and T cell types• Tumor cell in

  34. Slide 34: Pipeline

    ......·.·.·.·.·..•.•..• . i·.(·.;(•..R...ubiusTherapeutics •••••••••PIPELINE34

  35. Slide 35: Clinical-Stage Company Developing a Broad Wholly Owned Pipeline

    Clinical-Stage Company Developing a Broad Wholly Owned PipelinePRODUCT CATEGORYPROGRAMRTX-240PRECLINICALR/R Solid TumorsIND ENABLINGPHASE 1Phase 2 initiation 1Q’22*PHASE 2RTX-240R/R Acute Myeloid LeukemiaInitial clinical results by year-end*CANCERAUTOIMMUNE DISEASESRTX-240RTX-321 aAPC (HPV 16+)RTX-2

  36. Slide 36: Q&A and Appendix

    ......·.·.·.·.·..•.•..• . i·.(·.;(•..R...ubiusTherapeutics •••••••••Q&A AND APPENDIX36

  37. Slide 37: Supporting Rubius Preclinical Publications

    Supporting Rubius Preclinical Publications• RTX-240 ▪ 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting• RTX-321 ▪ 2020 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting; ▪ 2020 American Association for Cancer Research (AACR) Tumor Immunology Conference; and ▪ 2

  38. Slide 38: Red Cell Therapeutics Competitive Comparison Indicates Potential Advantages

    Red Cell Therapeutics Competitive Comparison Indicates Potential AdvantagesOutpatientSafety profile: No lymphodepletion, hospitalizations Safety profile: Narrow biodistribution Safety profile: No lentiviral genetic material present Safety profile: No severe liver or organ toxicity Broad anti-tumor i

  39. Slide 39: Methodology to Identify Target Cell Trafficking into Tumor Microenvironment

    Comprehensive and Precise Methodology to Identify Target Cell Trafficking into Tumor Microenvironment (TME) in Paired Biopsies*Tissue analysis area definedNuclei definedStroma (SOX10-)Tumor (SOX10+)12-plex stainsSTEP 1 STEP 2 STEP 3 STEP 4 STEP 5Define areas of analysis in tissue sectionsDefine necr

Rubius Therapeutics — Technical Presentation (March 2021) on 6ix